+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Urinary Incontinence Therapeutics Market Size, Share & Trends Analysis Report by Type (Stress Incontinence, Urge Incontinence), Drug Class, Gender, Distribution Channel and Region with Growth Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • November 2025
  • Region: Global
  • Grand View Research
  • ID: 5990617
REQUEST CUSTOMIZATION
Description Jump to:
The global urinary incontinence therapeutics market size was estimated at USD 4.32 billion in 2024 and is projected to reach USD 6.95 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. This growth is primarily driven by the increasing prevalence of urinary incontinence among aging populations and the growing demand for effective therapeutic interventions that address bladder dysfunction.

According to a May 2023 report by Dovepress, the prevalence of female urinary incontinence was found to be 24.8%, with stress incontinence accounting for 12.7%, mixed incontinence for 8.0%, and urgency incontinence for 4.1%. The study indicated that prevalence increased progressively with age and body mass index, emphasizing the need for early diagnosis and effective therapy. Rising awareness among patients and healthcare providers has improved diagnosis and management rates, supporting higher treatment adoption. Advancements in β3-adrenoceptor agonists and antimuscarinic agents are improving outcomes across patient groups, while wider access to oral and non-invasive options is enhancing adherence. Expanding retail and online pharmacy networks are ensuring consistent medication availability, reinforcing market performance across regions.

The market is expanding as pharmaceutical companies focus on developing targeted and safer therapies addressing persistent unmet needs. For instance, in April 2024, Lupin Ltd introduced Mirabegron, a generic alternative to Myrbetriq, aimed at managing overactive bladder in the U.S. The introduction of such generics and novel mechanisms of action is diversifying treatment options and improving accessibility. Investments in research programs to enhance efficacy and minimize side effects are creating opportunities for the development of differentiated therapies. The presence of branded and generic drugs ensures cost flexibility, improving treatment compliance. Strategic collaborations between leading players and research organizations are accelerating development timelines and expanding the therapeutic pipeline. Continuous lifecycle management and post-approval studies are reinforcing product positioning, sustaining long-term competitiveness, and revenue stability.

Market expansion is further supported by rising healthcare expenditures and increasing access to urology and women’s health services across both developed and emerging regions. For instance, in October 2025, global data showed that the number of people aged 60 and older is projected to double from 1 billion in 2020 to 2.1 billion by 2050. As this population segment grows, the burden of urinary incontinence and related geriatric conditions is expected to rise, driving demand for effective and accessible treatment options. Healthcare providers are prioritizing the quality of life of older adults through improved disease management, which is stimulating innovation in therapeutic strategies. Advancements in drug delivery technologies are improving treatment precision and convenience, while expanded clinical research in overactive bladder and mixed incontinence is driving the evolution of combination regimens. Sustained innovation, efficient distribution systems, and growing clinical adoption are expected to maintain a stable growth trajectory for the urinary incontinence therapeutics market through the forecast period.

Global Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global urinary incontinence therapeutics market report based on type, drug class, gender, distribution channel, and region:

Type Outlook (Revenue, USD Million, 2021-2033)

  • Stress Incontinence
  • Urge Incontinence
  • Overflow Incontinence
  • Functional Incontinence
  • Other Types

Drug Class Outlook (Revenue, USD Million, 2021-2033)

  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants
  • Other Drug Classes

Gender Outlook (Revenue, USD Million, 2021-2033)

  • Male
  • Female

Distribution ChannelOutlook (Revenue, USD Million, 2021-2033)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Drug Class
1.2.3. Gender
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Urinary Incontinence Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Urinary Incontinence Therapeutics Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2033
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Stress Incontinence
4.4.1. Stress Incontinence Market, 2021-2033 (USD Million)
4.5. Urge Incontinence
4.5.1. Urge Incontinence Market, 2021-2033 (USD Million)
4.6. Overflow Incontinence
4.6.1. Overflow Incontinence Market, 2021-2033 (USD Million)
4.7. Functional Incontinence
4.7.1. Functional Incontinence Market, 2021-2033 (USD Million)
4.8. Other Types
4.8.1. Other Types Market, 2021-2033 (USD Million)
Chapter 5. Urinary Incontinence Therapeutics Market: Drug Class Business Analysis
5.1. Drug Class Market Share, 2024 & 2033
5.2. Drug Class Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
5.4. Anticholinergics
5.4.1. Anticholinergics Market, 2021-2033 (USD Million)
5.5. Beta-3 Adrenoceptor Agonists
5.5.1. Beta-3 Adrenoceptor Agonists Market, 2021-2033 (USD Million)
5.6. Alpha Blockers
5.6.1. Alpha Blockers Market, 2021-2033 (USD Million)
5.7. Estrogen
5.7.1. Estrogen Market, 2021-2033 (USD Million)
5.8. Desmopressin
5.8.1. Desmopressin Market, 2021-2033 (USD Million)
5.9. Tricyclic Antidepressants
5.9.1. Tricyclic Antidepressants Market, 2021-2033 (USD Million)
5.10. Other Drug Classes
5.10.1. Other Drug Classes Market, 2021-2033 (USD Million)
Chapter 6. Urinary Incontinence Therapeutics Market: Gender Business Analysis
6.1. Gender Market Share, 2024 & 2033
6.2. Gender Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by gender, 2021 to 2033 (USD Million)
6.4. Male
6.4.1. Male Market, 2021-2033 (USD Million)
6.5. Female
6.5.1. Female Market, 2021-2033 (USD Million)
Chapter 7. Urinary Incontinence Therapeutics Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2021-2033 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2021-2033 (USD Million)
7.6. Online Pharmacies
7.6.1. Online Pharmacies Market, 2021-2033 (USD Million)
Chapter 8. Urinary Incontinence Therapeutics Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America Urinary Incontinence Therapeutics Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Gender Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. U.S. Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Gender Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. U.S. Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Gender Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. Mexico Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5. Europe
8.5.1. Europe Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Gender Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. UK Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Gender Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. Germany Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Gender Disease Prevalence
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement Framework
8.5.4.5. France Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Gender Disease Prevalence
8.5.5.3. Regulatory Framework
8.5.5.4. Reimbursement Framework
8.5.5.5. Italy Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Gender Disease Prevalence
8.5.6.3. Regulatory Framework
8.5.6.4. Reimbursement Framework
8.5.6.5. Spain Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. Gender Disease Prevalence
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement Framework
8.5.7.5. Denmark Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. Gender Disease Prevalence
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement Framework
8.5.8.5. Sweden Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Gender Disease Prevalence
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement Framework
8.5.9.5. Norway Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6. Asia-Pacific
8.6.1. Asia-Pacific Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Gender Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. Japan Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Gender Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. China Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Gender Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. India Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Gender Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Australia Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. Gender Disease Prevalence
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement Framework
8.6.6.5. South Korea Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Gender Disease Prevalence
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement Framework
8.6.7.5. Thailand Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.7. Latin America
8.7.1. Latin America Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Gender Disease Prevalence
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement Framework
8.7.2.5. Brazil Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Gender Disease Prevalence
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement Framework
8.7.3.5. Argentina Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Gender Disease Prevalence
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement Framework
8.8.2.5. South Africa Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Gender Disease Prevalence
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement Framework
8.8.3.5. Saudi Arabia Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Gender Disease Prevalence
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement Framework
8.8.4.5. UAE Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Gender Disease Prevalence
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement Framework
8.8.5.5. Kuwait Urinary Incontinence Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Pfizer Inc.
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. AbbVie Inc.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Astellas Pharma Inc.
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Johnson & Johnson
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Viatris Inc.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Teva Pharmaceutical Industries Ltd.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Sanofi S.A.
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. GlaxoSmithKline plc
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Boehringer Ingelheim Pharmaceuticals, Inc.
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Bayer AG
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
9.5.11. Ferring Pharmaceuticals
9.5.11.1. Overview
9.5.11.2. Financial Performance
9.5.11.3. Product Benchmarking
9.5.11.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global urinary incontinence therapeutics market, by region, 2021-2033 (USD Million)
Table 4 Global urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 5 Global urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 6 Global urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 7 Global urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 8 North America urinary incontinence therapeutics market, by country, 2021-2033 (USD Million)
Table 9 North America urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 10 North America urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 11 North America urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 12 North America urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 13 U.S urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 14 U.S urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 15 U.S urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 16 U.S urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 17 Canada urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 18 Canada urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 19 Canada urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 20 Canada urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 21 Mexico urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 22 Mexico urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 23 Mexico urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 24 Mexico urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 25 Europe urinary incontinence therapeutics market, by country, 2021-2033 (USD Million)
Table 26 Europe urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 27 Europe urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 28 Europe urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 29 Europe urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 30 UK urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 31 UK urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 32 UK urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 33 UK urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 34 Germany urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 35 Germany urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 36 Germany urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 37 Germany urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 38 France urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 39 France urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 40 France urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 41 France urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 42 Italy urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 43 Italy urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 44 Italy urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 45 Italy urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 46 Spain urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 47 Spain urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 48 Spain urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 49 Spain urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 50 Norway urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 51 Norway urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 52 Norway urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 53 Norway urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 54 Denmark urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 55 Denmark urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 56 Denmark urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 57 Denmark urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 58 Sweden urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 59 Sweden urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 60 Sweden urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 61 Sweden urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 62 Asia-Pacific urinary incontinence therapeutics market, by country, 2021-2033 (USD Million)
Table 63 Asia-Pacific urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 64 Asia-Pacific urinary incontinence therapeutics market, by drug class, 2021-2033, (USD
Table 65 Asia-Pacific urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 66 Asia-Pacific urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 67 Japan urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 68 Japan urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 69 Japan urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 70 Japan urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 71 China urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 72 China urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 73 China urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 74 China urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 75 India urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 76 India urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 77 India urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 78 India urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 79 Australia urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 80 Australia urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 81 Australia urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 82 Australia urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 83 South Korea urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 84 South Korea urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 85 South Korea urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 86 South Korea urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 87 Thailand urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 88 Thailand urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 89 Thailand urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 90 Thailand urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 91 Latin America urinary incontinence therapeutics market, by country, 2021-2033 (USD Million)
Table 92 Latin America urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 93 Latin America urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 94 Latin America urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 95 Latin America urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 96 Brazil urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 97 Brazil urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 98 Brazil urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 99 Brazil urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 100 Argentina urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 101 Argentina urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 102 Argentina urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 103 Argentina urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 104 Middle East & Africa Urinary incontinence therapeutics market, by country, 2021-2033 (USD Million)
Table 105 Middle East & Africa urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 106 Middle East & Africa urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 107 Middle East & Africa urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 108 Middle East & Africa urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 109 South Africa urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 110 South Africa urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 111 South Africa urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 112 South Africa urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 113 Saudi Arabia urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 114 Saudi Arabia urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 115 Saudi Arabia urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 116 Saudi Arabia urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 117 UAE urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 118 UAE urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 119 UAE urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 120 UAE urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 121 Kuwait urinary incontinence therapeutics market, by type, 2021-2033 (USD Million)
Table 122 Kuwait urinary incontinence therapeutics market, by drug class, 2021-2033 (USD Million)
Table 123 Kuwait urinary incontinence therapeutics market, by gender, 2021-2033 (USD Million)
Table 124 Kuwait urinary incontinence therapeutics market, by distribution channel, 2021-2033 (USD Million)
List of Figures
Figure 1 Urinary incontinence therapeutics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Competitive landscape
Figure 10 Urinary incontinence therapeutics market dynamics
Figure 11 Urinary incontinence therapeutics market: Porter’s five forces analysis
Figure 12 Urinary incontinence therapeutics market: PESTLE analysis
Figure 13 Type market, 2021-2033 (USD Million)
Figure 14 Stress Incontinence market, 2021-2033 (USD Million)
Figure 15 Urge Incontinence market, 2021-2033 (USD Million)
Figure 16 Overflow Incontinence market, 2021-2033 (USD Million)
Figure 17 Functional Incontinence market, 2021-2033 (USD Million)
Figure 18 Other Types market, 2021-2033 (USD Million)
Figure 19 Drug Class market, 2021-2033 (USD Million)
Figure 20 Anticholinergics market, 2021-2033 (USD Million)
Figure 21 Beta-3 Adrenoceptor Agonists market, 2021-2033 (USD Million)
Figure 22 Alpha Blockers market, 2021-2033 (USD Million)
Figure 23 Estrogen market, 2021-2033 (USD Million)
Figure 24 Desmopressin market, 2021-2033 (USD Million)
Figure 25 Tricyclic Antidepressants market, 2021-2033 (USD Million)
Figure 26 Other Drug Classes market, 2021-2033 (USD Million)
Figure 27 Gender market, 2021-2033 (USD Million)
Figure 28 Male market, 2021-2033 (USD Million)
Figure 29 Female market, 2021-2033 (USD Million)
Figure 30 Distribution Channel market, 2021-2033 (USD Million)
Figure 31 Hospital Pharmacies market, 2021-2033 (USD Million)
Figure 32 Retail Pharmacies market, 2021-2033 (USD Million)
Figure 33 Online Pharmacies market, 2021-2033 (USD Million)
Figure 34 Urinary incontinence therapeutics market revenue, by region
Figure 35 Regional marketplace: Key takeaways
Figure 36 North America urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 37 U.S. country dynamics
Figure 38 U.S. urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 39 Canada country dynamics
Figure 40 Canada urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 41 Mexico country dynamics
Figure 42 Mexico urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 43 Europe urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 44 UK country dynamics
Figure 45 UK urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 46 Germany country dynamics
Figure 47 Germany urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 48 France country dynamics
Figure 49 France urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 50 Italy country dynamics
Figure 51 Italy urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 52 Spain country dynamics
Figure 53 Spain urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 54 Norway country dynamics
Figure 55 Norway urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 56 Sweden country dynamics
Figure 57 Sweden urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 58 Denmark country dynamics
Figure 59 Denmark urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 60 Asia-Pacific urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 61 Japan country dynamics
Figure 62 Japan urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 63 China country dynamics
Figure 64 China urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 65 India country dynamics
Figure 66 India urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 67 Australia country dynamics
Figure 68 Australia urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 69 South Korea country dynamics
Figure 70 South Korea urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 71 Thailand country dynamics
Figure 72 Thailand urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 73 Latin America urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 74 Brazil country dynamics
Figure 75 Brazil urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 76 Argentina country dynamics
Figure 77 Argentina urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 78 Middle East & Africa urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 79 South Africa country dynamics
Figure 80 South Africa urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 81 Saudi Arabia country dynamics
Figure 82 Saudi Arabia urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 83 UAE country dynamics
Figure 84 UAE urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 85 Kuwait country dynamics
Figure 86 Kuwait urinary incontinence therapeutics market, 2021-2033 (USD Million)
Figure 87 Company categorization
Figure 88 Company market position analysis
Figure 89 Strategic framework

Companies Mentioned

The key companies profiled in this Urinary Incontinence Therapeutics market report include:
  • Pfizer Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bayer AG
  • Ferring Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages150
PublishedNovember 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 4.32 Billion
Forecasted Market Value ( USD ) by 2033 $ 6.95 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Male Urinary Incontinence Market Size, Share & Trends Analysis Report By Product, By Incontinence Type (Stress Urinary Incontinence, Urge Urinary Incontinence), By Usage, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Male Urinary Incontinence Market Size, Share & Trends Analysis Report By Product, By Incontinence Type (Stress Urinary Incontinence, Urge Urinary Incontinence), By Usage, By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 120 Pages
  • Global
From
Urinary Incontinence Drugs Market Report and Forecast 2025-2034 - Product Image

Urinary Incontinence Drugs Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Urinary Incontinence Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Urinary Incontinence Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 192 Pages
  • Global
From
Urinary Incontinence Therapeutics Market - Global Strategic Business Report - Product Image

Urinary Incontinence Therapeutics Market - Global Strategic Business Report

  • Report
  • 487 Pages
  • Global
From
Urinary Incontinence Drug Pipeline Analysis Report 2025 - Product Image

Urinary Incontinence Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From

About the Urinary Incontinence Drug Market

The Urinary Incontinence Drug market is a subset of the Urological Disorders Drugs market, which includes drugs used to treat a variety of conditions related to the urinary system. Urinary Incontinence Drugs are used to treat the involuntary leakage of urine, which can be caused by a variety of conditions, including overactive bladder, stress incontinence, and urge incontinence. These drugs can be administered orally, topically, or through injections. Commonly used drugs include anticholinergics, beta-3 agonists, and alpha-blockers. Some of the companies in the Urinary Incontinence Drug market include Allergan, Astellas Pharma, Pfizer, Merck, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.